Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
AssigneeBioCardia, Inc.
InventorsPeter Altman, Cheryl Wong Po Foo
Life of this patent
Estimating the term…
Abstract
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
Claims28
A method for screening a patient with chronic myocardial ischemia or heart failure of ischemic etiology to determine a likelihood that the patient's autologous bone marrow cells will be suitable for transplantation to a heterologous tissue site to treat the patient's chronic myocardial ischemia or heart failure of ischemic etiology, said method comprising:
- determining, with the aid of a cell counter, whether individual concentrations of at least one of CD19+, CD34+, or CD133+ cells in a phenotypic profile of bone marrow cells (BMC) in a sample of BMC from the patient with chronic myocardial ischemia or heart failure of ischemic etiology each meet or exceed threshold concentrations of at least one of CD19+, CD34+, or CD133+ cells, respectively, to identify the BMC from the patient with chronic myocardial ischemia or heart failure of ischemic etiology as being suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC to treat the patient's chronic myocardial ischemia or heart failure of ischemic etiology,
- wherein the phenotypic profile comprises a CD profile comprising the concentrations of at least one of CD19+, CD34+, or CD133+ cells, and
- wherein the BMC from the patient with chronic myocardial ischemia or heart failure of ischemic etiology are identified as suitable for said transplantation if each of the determined individual concentrations of the at least one of CD19+, CD34+, or CD133+ cells in the CD profile meet or exceed the threshold concentrations of the at least one of CD19+, CD34+, or CD133+ cells, respectively;
- and
- transplanting autologous BMC, which have been identified as suitable for transplantation and are from the patient with chronic myocardial ischemia or heart failure of ischemic etiology, to the heterologous tissue site of said patient without enriching particular phenotypic population(s) of said autologous BMC.
Dependencies are inferred from the claim text.